Defining the risks of mesenchymal stromal cell therapy
β Scribed by Prockop, Darwin J.; Brenner, Malcolm; Fibbe, Willem E.; Horwitz, Edwin; Le Blanc, Katarina; Phinney, Donald G.; Simmons, Paul J.; Sensebe, Luc; Keating, Armand
- Book ID
- 120971631
- Publisher
- Informa plc
- Year
- 2010
- Tongue
- English
- Weight
- 160 KB
- Volume
- 12
- Category
- Article
- ISSN
- 1465-3249
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Over the past decade, significant efforts have been made to develop stem cell-based therapies for difficult to treat diseases. Multipotent mesenchymal stromal cells, also referred to as mesenchymal stem cells (MSCs), appear to hold great promise in regards to a regenerative cell-based therapy for th
Over the past decade, significant efforts have been made to develop stem cell-based therapies for difficult to treat diseases. Multipotent mesenchymal stromal cells, also referred to as mesenchymal stem cells (MSCs), appear to hold great promise in regards to a regenerative cell-based therapy for th
Over the past decade, significant efforts have been made to develop stem cell-based therapies for difficult to treat diseases. Multipotent mesenchymal stromal cells, also referred to as mesenchymal stem cells (MSCs), appear to hold great promise in regards to a regenerative cell-based therapy for th